Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Tecentriq“
Suchtreffer
Begriffe & Kennungen
Tecentriq · 4.8 · Guillain-Barré syndrome and demyelinating polyneuropathy
Eintrag öffnenTecentriq · 4.8 · Guillain-Barré syndrome and demyelinating polyneuropathy occurred in 0.1% (6/5 039) of patients who received a
Eintrag öffnenTecentriq · 4.8 · Guillain-Barré syndrome and demyelinating polyneuropathy occurred in 0.1% (6/5 039) of patients who received a
Eintrag öffnenTecentriq · 4.8 · Hepatitis occurred in 1.7% (88/5 039) of patients who received atezolizumab monotherapy. Of the 88 patients, t
Eintrag öffnenTecentriq · 4.8 · Hepatitis occurred in 1.7% (88/5 039) of patients who received atezolizumab monotherapy. Of the 88 patients, t
Eintrag öffnenTecentriq · 4.8 · Hyperthyroidism occurred in 2.4% (121/5 039) of patients who received atezolizumab monotherapy. The median tim
Eintrag öffnenTecentriq · 4.8 · Hyperthyroidism occurred in 2.4% (121/5 039) of patients who received atezolizumab monotherapy. The median tim
Eintrag öffnenTecentriq · 4.8 · Hypophysitis
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.2% (9/5 039) of patients who received atezolizumab monotherapy. The median time to
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.2% (9/5 039) of patients who received atezolizumab monotherapy. The median time to
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.4% (2/473) of patients who received atezolizumab in combination with nab-paclitaxel
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.4% (2/473) of patients who received atezolizumab in combination with nab-paclitaxel
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.8% (3/393) of patients who received atezolizumab with bevacizumab, paclitaxel, and
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 0.8% (3/393) of patients who received atezolizumab with bevacizumab, paclitaxel, and
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 1.4% (15/1 093) of patients who received atezolizumab in combination with paclitaxel
Eintrag öffnenTecentriq · 4.8 · Hypophysitis occurred in 1.4% (15/1 093) of patients who received atezolizumab in combination with paclitaxel
Eintrag öffnenTecentriq · 4.8 · Hypothyroidism occurred in 8.5% (427/5 039) of patients who received atezolizumab monotherapy. The median time
Eintrag öffnenTecentriq · 4.8 · Hypothyroidism occurred in 8.5% (427/5 039) of patients who received atezolizumab monotherapy. The median time
Eintrag öffnenTecentriq · 4.8 · Immune checkpoint inhibitor class effects
Eintrag öffnenTecentriq · 4.8 · Immune checkpoint inhibitor class effects
Eintrag öffnen